Fujifilm gets $265M contract from BARDA, partners with Novavax

Fujifilm Diosynth Biotechnologies will receive $265 million in federal money to manufacture COVID-19 vaccines as part of Operation Warp Speed

Advertisement

The money came from the Biomedical Advanced Research and Development Authority, or BARDA, a divison of HHS. 

The Tokyo-based drugmaker also will manufacture 100 million vials of Novavax’s experimental coronavirus vaccine at its facility in Morrisville, N.C., the Washington Business Journal reported. 

The doses are being earmarked for Novavax’s phase 3 trial, which will include 30,000 people in the U.S.

More articles on pharmacy:
Pfizer CEO calls drug pricing executive orders ‘radical,’ an ‘enormous distraction’
10 best-selling drugs in the world by 2026
Walgreens says 180 stores affected by potential patient data breach

At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.

Register to Attend Webinar

The Performance Gap Your Pharmacy Training Metrics Can’t See

Monday, August 10
12:00 PM - 1:00 PM CDT

Presenters: Michael Alexander, AudirieDr. Tina Moen, PharmD, Colibri Healthcare

Advertisement

Next Up in Pharmacy

Advertisement

Comments are closed.